1. Home
  2. RCUS vs PRO Comparison

RCUS vs PRO Comparison

Compare RCUS & PRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • PRO
  • Stock Information
  • Founded
  • RCUS 2015
  • PRO 1985
  • Country
  • RCUS United States
  • PRO United States
  • Employees
  • RCUS N/A
  • PRO N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • PRO EDP Services
  • Sector
  • RCUS Health Care
  • PRO Technology
  • Exchange
  • RCUS Nasdaq
  • PRO Nasdaq
  • Market Cap
  • RCUS 906.4M
  • PRO 898.3M
  • IPO Year
  • RCUS 2018
  • PRO 2007
  • Fundamental
  • Price
  • RCUS $8.92
  • PRO $17.58
  • Analyst Decision
  • RCUS Buy
  • PRO Strong Buy
  • Analyst Count
  • RCUS 11
  • PRO 10
  • Target Price
  • RCUS $25.33
  • PRO $29.40
  • AVG Volume (30 Days)
  • RCUS 1.2M
  • PRO 575.6K
  • Earning Date
  • RCUS 05-06-2025
  • PRO 07-29-2025
  • Dividend Yield
  • RCUS N/A
  • PRO N/A
  • EPS Growth
  • RCUS N/A
  • PRO N/A
  • EPS
  • RCUS N/A
  • PRO N/A
  • Revenue
  • RCUS $141,000,000.00
  • PRO $336,006,000.00
  • Revenue This Year
  • RCUS N/A
  • PRO $10.25
  • Revenue Next Year
  • RCUS $29.83
  • PRO $10.47
  • P/E Ratio
  • RCUS N/A
  • PRO N/A
  • Revenue Growth
  • RCUS N/A
  • PRO 7.97
  • 52 Week Low
  • RCUS $6.50
  • PRO $14.81
  • 52 Week High
  • RCUS $18.98
  • PRO $30.67
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 53.03
  • PRO 48.93
  • Support Level
  • RCUS $8.42
  • PRO $16.69
  • Resistance Level
  • RCUS $9.61
  • PRO $18.33
  • Average True Range (ATR)
  • RCUS 0.49
  • PRO 0.56
  • MACD
  • RCUS 0.06
  • PRO 0.04
  • Stochastic Oscillator
  • RCUS 48.89
  • PRO 38.70

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About PRO PROS Holdings Inc.

Pros Holdings Inc. is a provider of cloud-based revenue and profit realization software solutions to business-to-business and business-to-consumer companies. Its solutions assist customers in growing revenue, modernizing business processes, and supporting profitability by leveraging prescriptive analytics and data science-based decision-making technology. The company's solutions enable buyers to move fluidly across its customers' direct sales, partner, online, mobile, and emerging channels with personalized experiences. The firm generates revenue in the United States, Europe, Africa, Asia-Pacific, and Middle East regions.

Share on Social Networks: